I'm with you on the US. We are headquartered in Australia, with...

First 9 Last

Share
Profile

Follow
jamwolf

5,975 Posts.

104

01/06/24

01:00

Post #: 74113992
Share

Originally posted by CM662 ↑

Great exposure.
ADR have been supplying the top Asthma centres in small numbers for years and have got not traction.
AZ/ADR have had a number of initiatives in the UK with Asthma in the community setting with no traction.
This is a repeat of trials done 10-15 years ago which already show the benefits on outcomes. This trial will recomfirm what is known.
What needs to change is 1) Funding 2) GP / community Dr engagement 3) Patient engagment 4) Pharma to see this adds value.
What it won't do is make any difference to success in the US which is the make or break market for ADR.
While giving credit for an interesting little project I still stand behind the fact its a distraction for ADRs limited resources when ALL their focus needs to be in the US.
Drip feeding ADR off small clinical trial revenues does not make a business and hides the underlying issues that have dogged the business since the IPO in 2015.

The new CEO needs to be bold, kill everything not US, put an aggressive plan together and go for it. Make it or break it!

Whats doing to make that really tough is getting enough funding out of the Austalia market that loves ADR but has grown tired and exhausted over the last 20 years; where retail investors have been diluted to death and the top 5 holders have everything to loose but nothing in terms of adding liquidity to move the SP to anything near where it needs to be to get a return. If there are "players" in the game then no chance.
While it would kill us the options of delisting or listing in the US may be the best options for ADR as a buisness but the worst option for investors.

Expand

I'm with you on the US. We are headquartered in Australia, with R&D I believe still in New Zealand. We have zero business in either country.

Our COO is in the UK, where we potter around with clinical trials but again in a market with no reimbursement. Our CFO is in Melbourne- not sure what he does but he has zero visibility with investors.

Surely both roles should be US based to support Mastoridis.

The market may well be coming right in the US - execution is the key risk.

ADR Price at posting: 1.6¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

OJC

SPC to merge with Original Juice Co and Nature One Dairy

There are more pages in this discussion • 32 more messages in this thread...

First 9 Last

Add ADR (ASX) to my watchlist

(20min delay)
Last 1.2¢		Change 0.000(0.00%)		Mkt cap ! $9.102M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
5	756844	1.2¢

Sellers (Offers)

Price($)	Vol.	No.
1.5¢	100000	1

View Market Depth

No.	Vol.	Price($)
5	756844	0.012
2	127894	0.011
1	299995	0.010
3	625560	0.009
1	120000	0.008

Price($)	Vol.	No.
0.015	100000	1
0.016	192719	4
0.017	469686	2
0.019	99985	1
0.022	304500	1

Last trade - 16.12pm 02/10/2024 (20 minute delay)

ADR (ASX) Chart

Day chart unavailable

I'm with you on the US. We are headquartered in Australia, with...

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

SPC to merge with Original Juice Co and Nature One Dairy

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I'm with you on the US. We are headquartered in Australia, with...

Top Stories

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

SPC to merge with Original Juice Co and Nature One Dairy

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News